Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Poster Schedule
Home
Poster Schedule
All Days
Sun, Sep 10
Mon, Sep 11
Poster Schedule
Type here to filter the list
Monday, September 11, 2023
5:00 PM - 7:00 PM
PT
100: Model-based Investigation on Allometric Scaling in Pediatric PK: The Effects of Sample Size, Sampling Scheme & Age Range
Favorite
5:00 PM - 7:00 PM
PT
101: Is the Current Dosing Regimen of Ropivacaine Administered through Erector Spinae Plane Blocks Safe?
Favorite
5:00 PM - 7:00 PM
PT
102: Ultra-High Performance Liquid Chromatography-Tandem Mass Spectrometry for the Simultaneous Detection of Conjugated Metabolites of Indoxyl & p-Cresol for Toxicokinetic Investigations
Favorite
5:00 PM - 7:00 PM
PT
103: Investigating Tacrolimus Population Pharmacokinetics in Adult Hispanic Renal Transplant Recipients
Favorite
5:00 PM - 7:00 PM
PT
104: Infant & Adult VRC07-523LS Population Pharmacokinetic Modeling to Predict HIV Prevention in Breastfed Infants
Favorite
5:00 PM - 7:00 PM
PT
105: Drug & Dietary Supplement Exposures During Pregnancy & Lactation in the United States Between 2011-2022
Favorite
5:00 PM - 7:00 PM
PT
106: Is There a Need for a Dedicated Pharmacokinetic Trial for a Drug in Obese Populations? A Drug Prioritization Decision Tree Framework
Favorite
5:00 PM - 7:00 PM
PT
107: A Combined Ex Vivo & Physiologically-based Pharmacokinetic Approach to Determine Fentanyl Dosing in Children on Continuous Renal Replacement Therapy
Favorite
5:00 PM - 7:00 PM
PT
108: Development of a Mechanistic-Physiologically Based Pharmacokinetic Platform Model to Guide Adult & Pediatric Dosing for Bispecific T Cell Engagers through Intravenous & Subcutaneous Administration
Favorite
5:00 PM - 7:00 PM
PT
109: A Comparison of Capillary Microsampling Devices Vs Venipuncture in a Single-Dose Clinical Pharmacokinetics Study of Large & Small Molecules
Favorite
5:00 PM - 7:00 PM
PT
110: Predicting Pregnancy Population Pharmacokinetics Using Machine Learning Algorithms
Favorite
5:00 PM - 7:00 PM
PT
111: How to Use Digital Twin Technology in Clinical Trial
Favorite
5:00 PM - 7:00 PM
PT
112: A Systemic Examination of Natural Language Processing Algorithms in Longitudinal Pharmacokinetic/Pharmacodynamic Analyses
Favorite
5:00 PM - 7:00 PM
PT
113: Digital Twin-Based Metaverse Clinical Trial Space: From Making Clinical Trials More Accessible to Using It as a New Clinical Trial Tool
Favorite
5:00 PM - 7:00 PM
PT
114: A Clinical Study to Evaluate the Feasibility of Decentralized Clinical Trial Elements in Korean Patients
Favorite
5:00 PM - 7:00 PM
PT
115: Development of Electronic Patient Reported Outcome for Symptom Assessment in Severe Fever With Thrombocytopenia Syndrome Patients in Routine Clinical Practice
Favorite
5:00 PM - 7:00 PM
PT
116: A Multi-layer AI Algorithm that Transcribes SDTM Data into Full-length CSR
Favorite
5:00 PM - 7:00 PM
PT
117: Efficacy, Safety, Pharmacokinetic (PK) & Pharmacodynamic (PD) Support for Talquetamab Weekly (QW) & Biweekly (Q2W) Dosing in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Analyses From MonumenTAL-1
Favorite
5:00 PM - 7:00 PM
PT
118: Assessment of Anti-Drug Antibody Incidence in Subcutaneously Administered Antibody-Based Therapeutics Approved Between 2010-2022
Favorite
5:00 PM - 7:00 PM
PT
119: Impact of Inflammatory Diseases on the Pharmacokinetics of Therapeutic Proteins
Favorite
5:00 PM - 7:00 PM
PT
121: Monoclonal Antibodies for Treatment & Prevention of Infectious Diseases: An Overview of Clinical Pharmacology Contributions & Opportunities
Favorite
5:00 PM - 7:00 PM
PT
122: Genome-Wide Mapping of 5-methylcytosine and 5-hydroxymethylcytosine in Acute Myeloid Leukemia Primary Samples & Cord Blood Cells
Favorite
5:00 PM - 7:00 PM
PT
123: Pharmacogenomics of β-lactam Antibiotic-induced Severe Cutaneous Adverse Reactions
Favorite
5:00 PM - 7:00 PM
PT
124: Pharmacokinetics & Pharmacodynamics of Casirivimab & Imdevimab in Pregnant Outpatients With COVID-19
Favorite
5:00 PM - 7:00 PM
PT
125: Pharmacokinetics & Pharmacodynamics of Casirivimab &Imdevimab in Pediatric Outpatients With COVID-19
Favorite
5:00 PM - 7:00 PM
PT
126: Evaluation of Talquetamab Drug-Drug Interaction Potential as a Result of Cytokine Release Syndrome in Patients With Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model
Favorite
5:00 PM - 7:00 PM
PT
127: Clinical & Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib as a Victim of Drug-Drug Interactions in Cancer Patients
Favorite
5:00 PM - 7:00 PM
PT
128: Probing CYP3A4 Drug Metabolism Change in Patients With Obesity Undergoing Weight-Loss Using a Micro-Dose of Midazolam
Favorite
5:00 PM - 7:00 PM
PT
129: Clinical & Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib as a Perpetrator of Drug-Drug Interactions in Cancer Patients
Favorite
5:00 PM - 7:00 PM
PT
130: PBPK Model Development & Simulations to Predict Drug-Drug Interactions of Atogepant
Favorite
5:00 PM - 7:00 PM
PT
131: Intramuscular Triamcinolone Acetonide (Kenalog®): A Conundrum Amongst Corticosteriods
Favorite
5:00 PM - 7:00 PM
PT
132: Limited Potential for Interactions Between Trofinetide, a New Treatment for Rett Syndrome, & Drugs Metabolized By CYP3A4
Favorite
5:00 PM - 7:00 PM
PT
133: Assessment of the Effect of P-gp Inhibition on Pharmacokinetics of the RET Inhibitor, Pralsetinib, in Healthy Subjects
Favorite
5:00 PM - 7:00 PM
PT
134: Lack of Consistency in Pharmacokinetic Drug-Drug Interaction Management With CYP3A Substrates in Phase II/III Clinical Trials: A Call for Regulatory Guidance
Favorite
5:00 PM - 7:00 PM
PT
135: Methods to Assess QT/QTc Prolongation in Oncology Clinical Development: A Landscape Analysis of Approved Oncology Therapeutics
Favorite
5:00 PM - 7:00 PM
PT
137: Landscape Analysis of Adverse Events & Dose Intensity for FDA Approved Oncology Small Molecules
Favorite
5:00 PM - 7:00 PM
PT
138: A Thorough QT Study Using C-QTc to Evaluate the Effects of Centanafadine on Cardiac Repolarization
Favorite
5:00 PM - 7:00 PM
PT
139: Examining #Pharmacovigilance in the Era of COVID-19: A Hashtag Analysis Study
Favorite
5:00 PM - 7:00 PM
PT
142: Population Pharmacokinetic-Pharmacodynamic (PKPD) Modeling Analyses of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Solid Tumors
Favorite
5:00 PM - 7:00 PM
PT
143: A Meta-Analysis to Understand the Correlation Between Weight Loss & Resolution of Nonalcoholic Steatohepatitis
Favorite
5:00 PM - 7:00 PM
PT
144: A Concentration-QT Analysis Identifies No Meaningful Effect of Nirogacestat or Itraconazole on QTcF Interval
Favorite
5:00 PM - 7:00 PM
PT
145: An Evaluation of POPPK & PBPK Model-based Virtual Controls to Replace Healthy Subject Controls in Organ Impairment PK Studies
Favorite
5:00 PM - 7:00 PM
PT
146: Clinical PK Sampling Strategies, Precise Accurate Estimates of Population Clearance. Is Trough Sampling Enough? Practical NOT Optimal Sampling
Favorite
5:00 PM - 7:00 PM
PT
147: A Clinical Quantitative Systems Pharmacology Framework Describing Loncastuximab Tesirine Distribution & to Explore Patient Outcomes from the Lotis-2 Clinical Trial in Patients With B-Cell Lymphomas
Favorite
5:00 PM - 7:00 PM
PT
148: PK/PD Modeling of Progranulin Elevation in Blood & CSF to Support AL101 Dose Selection & Phase 2 Study Design
Favorite
5:00 PM - 7:00 PM
PT
149: Bioequivalence Safe Space Assessment of Molnupiravir & NHC Using Physiologically Based Biopharmaceutics Modeling
Favorite
5:00 PM - 7:00 PM
PT
150: Real-World Application of Physiologically Based Pharmacokinetic Modeling (PBPK) in Support of Decision-Making During Drug Discovery; Guidance & Recommendations for the Utility of PBPK Impact on Candidate Selection & Human Pharmacokinetic Prediction Through Case Examples
Favorite
5:00 PM - 7:00 PM
PT
151: Evaluating Clinical Impact of Hormonal Contraceptive Drug-Drug Interactions/Obesity on Ovulation Rate & Pearl Index Using Integrated Physiologically-based Pharmacokinetic Modeling & Model Based Meta-Analysis Approach
Favorite
5:00 PM - 7:00 PM
PT
152: Inhibition of the Complement Alternative Pathway in Healthy Subjects by an Oral Factor D Inhibitor
Favorite
5:00 PM - 7:00 PM
PT
153: Proof of Mechanism & Pharmacodynamic Fingerprinting; Relating 7,000 Protein Measurements to Disease & Pharmacology: An Example Using the Impact of Peginterferon on Influenza A Pathway
Favorite
5:00 PM - 7:00 PM
PT
154: Early Clinical Pharmacokinetic/Pharmacodynamic Modeling & Simulation of Povetacicept, a Potent Dual BAFF/APRIL Antagonist, to Support First-in-Disease Clinical Trials in Autoimmune Glomerulonephritis & Cytopenias
Favorite
5:00 PM - 7:00 PM
PT
155: Novel Gut-Brain Axis for Craving, Alcohol Withdrawal & Withdrawal-Associated Depression in Patients With Alcohol Use Disorder
Favorite
5:00 PM - 7:00 PM
PT
156: Dimethoxycurcumin Induces Global DNA Hydroxymethylation & Increases the Activity of TET Enzymes in Leukemia Cells
Favorite
5:00 PM - 7:00 PM
PT
157: Self-perceived Differential Effects of Kratom (Mitragyna speciosa Korth) “Strains” Do Not Correlate With Alkaloid Content
Favorite
5:00 PM - 7:00 PM
PT
159: Statin Prescribing Trends, Utilization & Expenditure in English Hospitals: A Retrospective Study Using a Large National Database
Favorite
5:00 PM - 7:00 PM
PT
163: The Effect of Food & the Proton Pump Inhibitor (PPI) Esomeprazole on the Single-Dose Pharmacokinetics (PK) and Safety of the PROteolysis Targeting Chimera (PROTAC) Androgen Receptor (AR) Degrader Bavdegalutamide in Healthy Volunteers
Favorite
5:00 PM - 7:00 PM
PT
164: Riluzole in Acute Spinal Cord Injury Study (RISCIS) With the Bayesian Approach to Overcome Small Sample Size & Inter-subject Variability
Favorite
5:00 PM - 7:00 PM
PT
165: No Clinically Meaningful Pharmacokinetic Drug-Drug Interaction between Berotralstat & the Progestin Oral Contraceptive Desogestrel
Favorite
5:00 PM - 7:00 PM
PT
166: The Effect of Food & the Proton Pump Inhibitor (PPI) Esomeprazole on the Single-Dose Pharmacokinetics (PK) & Safety of ARV-766, a PROteolysis Targeting Chimera (PROTAC) Androgen Receptor (AR) Degrader, in Healthy Volunteers
Favorite
5:00 PM - 7:00 PM
PT
167: Pharmacokinetics, Pharmacodynamics & Exposure- Response for Neurotoxicity Adverse Events in a Phase Ib/II CARTITUDE-1 Open-Label Study
Favorite
5:00 PM - 7:00 PM
PT
168: Population Pharmacokinetic/Pharmacodynamic Analysis of MDM2 Inhibitor Navtemadlin (KRT-232) in Combination with Decitabine in a Phase 1 Dose Escalation Study of Subjects With Acute Myeloid Leukemia
Favorite
5:00 PM - 7:00 PM
PT
169: The Effect of Rabeprazole, a Proton-Pump Inhibitor, on the Pharmacokinetics of Dordaviprone in Healthy Adult Participants
Favorite
5:00 PM - 7:00 PM
PT
170: A Target-mediated Drug Disposition Model to Explain the Nonlinear Pharmacokinetics of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Inhibitor BI-187004 in Healthy Subjects
Favorite
5:00 PM - 7:00 PM
PT
171: Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open-Label, Phase 1 Study
Favorite
5:00 PM - 7:00 PM
PT
173: Pharmacokinetic & Pharmacodynamic Modeling of QY201, a JAK1/TYK2 Inhibitor, in Healthy Chinese Adults
Favorite
5:00 PM - 7:00 PM
PT
174: A Population Pharmacokinetic Analysis to Evaluate the Effect of Race (Japanese vs Non-Asian) on Exposure of Low-Sodium Oxybate
Favorite
5:00 PM - 7:00 PM
PT
175: Drug-Drug Interaction (DDI) Study of the PROteolysis Targeting Chimera (PROTAC) Androgen Receptor (AR) Degrader Bavdegalutamide in Combination With the CYP3A4 Inhibitor Itraconazole in Healthy Volunteers
Favorite
5:00 PM - 7:00 PM
PT
177: The Effect of a High-Fat Meal on the Pharmacokinetics of Dordaviprone in Healthy Adult Participants
Favorite
5:00 PM - 7:00 PM
PT
178: In Silico Physiologically Based Pharmacokinetic Model of the Effect of Hepatic Impairment on Trofinetide Exposures
Favorite
5:00 PM - 7:00 PM
PT
179: Phase 1 Study Evaluating the Bioequivalence of the Dispersible Final Market Image Macitentan Tablet & the Opsumit® Tablet in Fasted Conditions
Favorite
5:00 PM - 7:00 PM
PT
180: Comparative Structure, In Vitro Efficacy & Pharmacokinetics of HSK3486 & Propofol
Favorite
5:00 PM - 7:00 PM
PT
181: Relative Bioavailability & Food Effect of Phase 2 Formulations of Zimlovisertib in Healthy Participants
Favorite
5:00 PM - 7:00 PM
PT
182: Pharmacokinetics of RBN-3143 in Healthy Adults, A Novel Mono (ADP-Ribose) Polymerase-14 (PARP14) Inhibitor
Favorite
5:00 PM - 7:00 PM
PT
183: Pharmacokinetics & Viral Shedding of an Oncolytic Virus (MEDI5395) in a Phase 1 Clinical Study
Favorite
5:00 PM - 7:00 PM
PT
184: Population Pharmacokinetic Modelling of RP-6306, a Novel PKMYT1 Inhibitor, in Cancer Patients from a Phase 1 Dose Escalation Study
Favorite
5:00 PM - 7:00 PM
PT
186: Population Pharmacokinetic Modeling of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Solid Tumors
Favorite
5:00 PM - 7:00 PM
PT
187: A Phase 1, Open-label, Single Ascending Dose Study to Evaluate the Pharmacokinetics of Vorasidenib in Healthy Japanese & Non-Asian Participants
Favorite
5:00 PM - 7:00 PM
PT
189: Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer
Favorite
5:00 PM - 7:00 PM
PT
190: Kick-starting Reporting of Pharmacokinetic Results With Simulated Concentration-Time Data
Favorite
5:00 PM - 7:00 PM
PT
191: Assessing Pediatric Vancomycin Exposures & the Influences of Body Composition
Favorite
5:00 PM - 7:00 PM
PT
192: Unraveling the Roadmap for Amikacin TDM in Critically Ill Cancer Patients
Favorite
5:00 PM - 7:00 PM
PT
193: Microdosed Yohimbine as CYP2D6 Probe Drug in Pediatric Heart Patients Aged 6 Months to 6 Years
Favorite
5:00 PM - 7:00 PM
PT
195: Protamine Protects Against Vancomycin Induced Kidney Injury in a Translational Rat Model
Favorite
5:00 PM - 7:00 PM
PT
196: Predictive Physiologically Based Pharmacokinetic (PBPK) Model Suggests Minimal Drug-Drug Interaction (DDI) Between PPARδ Agonist Mavodelpar (REN001) & Rosuvastatin
Favorite
5:00 PM - 7:00 PM
PT
197: Evaluation of the Impact of Physiological Changes of Pregnancy & Cancer on Oncology Drug Pharmacokinetics Towards Implementing a “Cancer-Pregnancy Physiologically Based Pharmacokinetic (PBPK) Population Model”
Favorite
5:00 PM - 7:00 PM
PT
199: A PBPK-Driven Modeling Approach for Extrapolation of Clinical Pharmacokinetic Results for Oral Nicotine-Containing Products
Favorite
